Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Solara Active Pharma Sciences Ltd (SOLARA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 541540 NSE: SOLARA Pharmaceuticals & Drugs | Small Cap | Solara Active Pharma Share Price
₹640.25 -2.35 (-0.37%)
As on 02-Sep'26 11:27
Solara Active Pharma Sciences Ltd (SOLARA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 541540 NSE: SOLARA Pharmaceuticals & Drugs | Small Cap | Solara Active Pharma Share Price
₹640.25 -2.35 (-0.37%)
As on 02-Sep'26 11:27
Key Metrics
Valuation Multiples
Market Cap
₹3,101 Cr.
Current Price
₹640.3
52-Week Low / High
₹423 / 711
TTM EPS
₹-0.3
TTM Sales
₹1,431 Cr.
Book Value per Share
₹263.3
P/E Ratio
0.00
Industry PE
54.5
Price to Book (P/B)
2.44
Higher than its 5-year historical median
Price to Sales (P/S)
2.17
Higher than its 5-year historical median
EV/EBITDA
18.61
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-0.63%
Underperforms industry median
Return on Capital Employed (ROCE)
4.61%
Underperforms industry median
Return on Assets (ROA)
-0.32%
Operating Profit Margin
13.7%
Net Profit Margin
-0.54%
Gross Profit Margin
6.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
6.64%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-9.47%
Net Profit Growth (1 Year)
-
-1472.22%
Asset Quality
Promoter Holding
41.93%
Pledged shares (%) of Promoter's holding (%)
37.11%
Reserves
₹1,222 Cr.
Equity
₹48.3 Cr.
Face Value
₹10
All Time Low / High
₹123.04 / 1713.61
Check Before You Invest
Quality
Not GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is Solara Active Pharma Sciences Ltd a good quality company?
Solara Active Pharma Sciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Solara Active Pharma Sciences Ltd performance compare with that of its Peers?
Revenue growth of Solara Active Pharma Sciences Ltd vs industry peers?
Solara Active Pharma Sciences Ltd revenue CAGR is -0.58%, compared to the industry median CAGR of 5.82%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Solara Active Pharma Sciences Ltd?
Promoters hold 41.93% of the Solara Active Pharma Sciences Ltd, with 37.11% of their stake pledged, indicating high pledge risk.
Stock return of Solara Active Pharma Sciences Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -15.48% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Solara Active Pharma Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 2.2% | 10.4% | 11.7% | 15.3% | -0.7% | 1.8% | -17.3% | 6.1% | 4.6% | - |
| Value Creation Index ⓘ | NA | -0.8 | -0.3 | -0.2 | 0.1 | -1.1 | -0.9 | -2.2 | -0.6 | -0.7 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,431 |
| Sales YoY Gr. | - | NA | 166.2% | -4.7% | 22.3% | -21.6% | 13.8% | -10.7% | -0.4% | 6.6% | - |
| Adj EPS ⓘ | 0 | 2.2 | 26.4 | 38.1 | 56.7 | -15.3 | -5.8 | -111.3 | -0.2 | -1.1 | -0.3 |
| YoY Gr. | - | NA | 1087.8% | 44.4% | 48.9% | -127% | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 0 | 285.4 | 303.8 | 338.2 | 406.5 | 390.1 | 383.8 | 238.7 | 271 | 280.3 | 263.3 |
| Adj Net Profit ⓘ | 0 | 6 | 73.8 | 111 | 221 | -59.6 | -22.6 | -435 | -0.9 | -5.2 | -2 |
| Cash Flow from Ops. ⓘ | 0 | 49.2 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 | - |
| Debt/CF from Ops. ⓘ | 0 | 12.9 | 3.2 | 2.9 | 3.9 | -4.2 | 6.4 | 9.2 | 3.7 | 4.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | -3.3% | -1.8% | 6.6% | ||||
| Adj EPS ⓘ | NA | -145.3% | NA | NA | ||||
| BVPSⓘ | NA | -7.2% | -10% | 3.4% | ||||
| Share Price | - | -15.6% | 24.7% | 1.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0.8 | 8.6 | 10.9 | 16.5 | -3.8 | -1.5 | -35.8 | -0.1 | -0.4 | -0.1 |
| Op. Profit Mgn % ⓘ | 0 | 12 | 16.6 | 19.8 | 24 | 6.4 | 9.3 | -7.4 | 16.1 | 13.7 | 13.4 |
| Net Profit Mgn % ⓘ | 0 | 1.1 | 5.3 | 8.4 | 13.7 | -4.7 | -1.6 | -33.7 | -0.1 | -0.4 | -0.1 |
| Debt to Equity ⓘ | 0 | 0.8 | 0.6 | 0.7 | 0.4 | 0.7 | 0.7 | 1.1 | 0.7 | 0.5 | - |
| Working Cap Days ⓘ | 0 | 0 | 163 | 177 | 178 | 312 | 310 | 264 | 206 | 205 | 107 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 40 | 64 | 70 | 189 | 194 | 163 | 85 | 103 | -7 |
Valuation of Solara Active Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 47.99 | 38.28 | 38.00 | 40.74 | 34.64 | 38.95 | 35.32 | 26.04 | 31.57 | 37.11 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 |
| Operating Expenses ⓘ + | 458 | 1,166 | 1,062 | 1,231 | 1,188 | 1,310 | 1,384 | 1,077 | 1,182 |
| Operating Profit ⓘ | 62 | 221 | 259 | 386 | 80 | 134 | -95 | 206 | 187 |
| Operating Profit Margin (%) | 12.0% | 15.9% | 19.6% | 23.9% | 6.3% | 9.3% | -7.4% | 16.1% | 13.6% |
| Other Income ⓘ + | 2 | 12 | 28 | 29 | 20 | 23 | 5 | 8 | 6 |
| Interest ⓘ | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 |
| Depreciation ⓘ | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 |
| Profit Before Tax ⓘ | 6 | 68 | 115 | 222 | -91 | -45 | -488 | 1 | -7 |
| Tax ⓘ | -0 | 1 | 0 | 0 | -33 | -23 | 79 | 0 | 0 |
| Profit After Tax | 6 | 67 | 115 | 221 | -58 | -22 | -567 | 1 | -7 |
| PAT Margin (%) | 1.2% | 4.8% | 8.7% | 13.7% | -4.6% | -1.5% | -44.0% | 0.0% | -0.5% |
| Adjusted EPS (₹) | 0.1 | 21.3 | 39.3 | 56.8 | -14.9 | -5.7 | -145.0 | 0.1 | -1.7 |
| Dividend Payout Ratio (%) | 0% | 21.70% | 4.70% | 11.40% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 764 | 849 | 985 | 1,585 | 1,524 | 1,499 | 932 | 1,091 | 1,247 | ||
| Debt + | 573 | 439 | 587 | 516 | 893 | 884 | 866 | 687 | 611 | ||
| Minority Interest | 4 | 4 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | ||
| Trade Payables | 313 | 244 | 216 | 309 | 276 | 306 | 313 | 248 | 274 | ||
| Others Liabilities ⓘ | 167 | 422 | 361 | 174 | 195 | 130 | 237 | 204 | 197 | ||
| Total Liabilities ⓘ | 1,821 | 1,960 | 2,153 | 2,588 | 2,890 | 2,821 | 2,351 | 2,232 | 2,333 | ||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 1,063 | 1,189 | 1,368 | 1,356 | 1,332 | 1,340 | 1,266 | 1,191 | 1,238 | ||
| CWIP ⓘ | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 | ||
| Investments ⓘ | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 | ||
| Inventories | 188 | 214 | 280 | 295 | 576 | 558 | 360 | 318 | 318 | ||
| Trade Receivables | 263 | 289 | 227 | 484 | 490 | 537 | 349 | 327 | 439 | ||
| Cash Equivalents | 47 | 76 | 57 | 199 | 47 | 9 | 9 | 4 | 50 | ||
| Others Assets ⓘ | 189 | 151 | 181 | 166 | 206 | 137 | 111 | 110 | 79 | ||
| Total Assets ⓘ | 1,821 | 1,960 | 2,153 | 2,588 | 2,890 | 2,821 | 2,351 | 2,232 | 2,333 | ||
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 |
| Cash Flow From Investing Activity ⓘ + | -85 | -116 | -359 | -106 | -243 | -81 | -4 | -37 | -99 |
| Cash Flow From Financing Activity ⓘ + | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 |
| Net Cash Flow ⓘ | 31 | 27 | -20 | 142 | -151 | -38 | -0 | -4 | 1 |
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 0.78 | 8.32 | 12.48 | 17.23 | -3.75 | -1.47 | -46.64 | 0.05 | -0.63 | |
| ROCE (%) | 2.22 | 10.38 | 11.73 | 15.34 | -0.67 | 1.79 | -17.29 | 6.07 | 4.61 | |
| Asset Turnover Ratio | 0.29 | 0.73 | 0.64 | 0.68 | 0.46 | 0.51 | 0.54 | 0.6 | 0.62 | |
| PAT to CFO Conversion(x) | 8.17 | 2.48 | 2.1 | 0.7 | N/A | N/A | N/A | 213 | N/A | |
| Working Capital Days | ||||||||||
| Receivable Days | 183.90 | 72.60 | 71.20 | 80.20 | 140.10 | 129.80 | 116.40 | 89.60 | 98.70 | |
| Inventory Days | 131.50 | 52.90 | 68.20 | 64.90 | 125.30 | 143.30 | 120.60 | 89.90 | 82 | |
| Payable Days | 420.20 | 144.30 | 140.30 | 132.40 | 163.40 | 134.60 | 140.30 | 163.30 | 139 | |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Solara Active Pharma Sciences Ltd FAQs
The current trading price of Solara Active Pharma on 02-Sep-2026 11:27 is ₹640.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Sep-2026 the market cap of Solara Active Pharma stood at ₹3,100.6 Cr
The latest P/E ratio of Solara Active Pharma as of 01-Sep-2026 is 0.00.
The latest P/B ratio of Solara Active Pharma as of 01-Sep-2026 is 2.43.
The 52-week high of Solara Active Pharma is ₹711.2 and the 52-week low is ₹422.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Solara Active Pharma is ₹1,431 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Solara Active Pharma Sciences Ltd is a below average quality company.
The key valuation ratios of Solara Active Pharma Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Solara Active Pharma Sciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences is a dynamic, entrepreneurial and customer-oriented API manufacturer. It has a legacy of over three decades and trace its origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd.
The company is poised to bridge the industry gap by delivering value-based products while maintaining focus on customer needs. It has hundreds of scientists working at its two R&D Centers and many API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities.
The company has a highly compliant manufacturing footprint spread over six large scale multi-product facilities. The company’s business is spread across several countries with extensive operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa.
Business area of the company
The company is a global, R&D focused, pureplay API company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies.
Products and services
- Commercial and R&D products
- Contract research and Manufacturing
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
